Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia
Laura Gragnani, Marcella Visentini, Elisa Fognani, Teresa Urraro, Adriano De Santis, Luisa Petraccia, Marie Perez, Giorgia Ceccotti, Stefania Colantuono, Milica Mitrevski, Cristina Stasi, Martina Del Padre, Monica Monti, Elena Gianni, Alessandro Pulsoni, Massimo Fiorilli, Milvia Casato, Anna Linda Zignego – 2 August 2016 – Hepatitis C virus (HCV)‐associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon virus eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic responses (SVR).